NICE postpones erenumab appraisal discussion in response to large volume of comments

The National Institute for Health and Care Excellence (NICE) in the UK has announced that it will reschedule discussion of its erenumab (Aimovig) appraisal owing to the high volume of comments received following publication of its draft guidance last month.

Read more »

Ajovy (fremanezumab) moves closer to EU approval

Ajovy (fremanezumab) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) which advises the European Commission on market authorisation of new medicines.

Read more »

New studies report contrasting findings on link between age of migraine onset and stroke risk

Increased stroke risk in people with migraine has been reported in multiple studies, and previous research has suggested that those who develop migraine at a young age are at greatest risk. However, data from a post hoc analysis from the Atherosclerosis Risk in Communities (ARIC) study have shown that individuals who developed migraine with aura in later life (> 50 years, with average duration 4.75 years) were at least twice as likely to have an ischaemic stroke than those who did not have headaches.

Read more »

CGRP trial meta analysis focuses on responder rates

It’s still early days for meta analyses of CGRP clinical trial data, but a recently published pooled analysis of data from over 3000 participants in Phase 2 and 3 studies of erenumab, fremanezumab and galcanezumab has reinforced previously reported beneficial effects on responder rates.

Read more »

For all the other recent migraine news featured on the CGRP Forum click here »